Clinical Efficacy of Ifosfamide-Based Regimen in Refractory of Relapsed Ovarian Cancer.
- Author:
Hyo Pyo LEE
;
Noh Hyun PARK
;
Jae Weon KIM
;
Seo Young PARK
;
Yong Sang SONG
;
Soon Beom KANG
- Publication Type:Original Article
- Keywords:
ovarian cancer;
refractory;
relapse;
cisplatin;
ifosfamide
- MeSH:
Cisplatin;
Drug Therapy, Combination;
Humans;
Ifosfamide;
Mesna;
Ovarian Neoplasms*;
Recurrence;
Salvage Therapy
- From:Korean Journal of Gynecologic Oncology and Colposcopy
1996;7(4):263-269
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
This phase II study aimed to assess the clinical activity and toxicity of ifosfamide based regimen in patients with epithelial ovarian cancer, relapsed or refractory to cisplatin-containing combination chemotherapy. From July 1991 to June 1993, 18 patients with epithelial ovarian cancer, relapsed or refractory to cisplatin were treated as follows. Relapsed cases were treated with IP(ifosfamide 4,0g/m2 intravenously and cisplatin 60mg/m2 intravenously on day 1) regimen every 3-4 weeks. The regimen used in refractory cases was Et-I(etoposide 100mg/m2 intravenously on days 1 to 3 and ifosfamide 1.0g/m2 intravenously on days 1 to 5) regimen every 3 or 4 weeks. The uroprotectant mesna was concomitantly used. Responses and toxicities were evaluated according to the WHO Criteria. The overall response rate was 27.8%(5/18), including 2 complete response and 3 partial response. There were four episodes(22.2%) of grade 3, 4 myelosuppression, but no other grade 3, 4 non-hematologic toxicity. Salvage therapy with ifosfamide based regimen is a useful and well tolerated treatment strategy in selected patients with relapsed ovarian cancer.
